Shimura Tatsuo, Shibata Masahiko, Gonda Kenji, Okayama Hirokazu, Saito Motonobu, Momma Tomoyuki, Ohki Shinji, Kono Koji
Department of Progressive DOHaD Research, Fukushima Medical University, Fukushima, Fukushima, Japan.
Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima, Fukushima, Japan.
J Surg Res. 2018 Jul;227:145-150. doi: 10.1016/j.jss.2018.02.035. Epub 2018 Mar 15.
The goal of the present study was to determine whether serum transthyretin level can be used as a novel prognostic biomarker for patients with gastric cancer.
Serum levels of transthyretin were examined before treatment in 42 patients with gastric cancer, 30 of whom underwent curative operation and had their prognostic factors analyzed.
In an analysis using a receiver operating characteristic curve, transthyretin was evaluated as a useful biomarker to predict the overall survival of the patients (P = 0.033), and a level of 22.8 mg/dL was determined as the cut off value. The transthyretin levels exhibited statistically significant correlations with total protein (r = 0.598, P < 0.001), albumin (r = 0.626, P < 0.001), and retinol binding protein (r = 0.753, P < 0.001). On the other hand, the transthyretin levels showed statistically significant inverse correlations with tumor size (r = -0.753, P < 0.001) and the numbers of involved lymph nodes (r = -0.453, P = 0.012). The patients with serum transthyretin levels of <22.8 mg/dL showed poorer prognosis than those with levels of ≥22.8 mg/dL (P = 0.033); therefore, serum transthyretin level was an independent prognostic factor for the gastric cancer patients (hazard ratio: 0.420, 95% confidence interval: 0.180-0.985, P = 0.042).
Anthropometric measurement of serum transthyretin can be useful for predicting the prognosis of patients with gastric cancer.
本研究的目的是确定血清甲状腺素运载蛋白水平是否可作为胃癌患者一种新的预后生物标志物。
对42例胃癌患者治疗前的血清甲状腺素运载蛋白水平进行检测，其中30例接受了根治性手术，并对其预后因素进行分析。
在一项使用受试者工作特征曲线的分析中，甲状腺素运载蛋白被评估为预测患者总生存期的有用生物标志物（P = 0.033），并确定22.8mg/dL为临界值。甲状腺素运载蛋白水平与总蛋白（r = 0.598，P < 0.001）、白蛋白（r = 0.626，P < 0.001）和视黄醇结合蛋白（r = 0.753，P < 0.001）呈统计学显著相关。另一方面，甲状腺素运载蛋白水平与肿瘤大小（r = -0.753，P < 0.001）和受累淋巴结数量（r = -0.453，P = 0.012）呈统计学显著负相关。血清甲状腺素运载蛋白水平<22.8mg/dL的患者预后比水平≥22.8mg/dL的患者差（P = 0.033）；因此，血清甲状腺素运载蛋白水平是胃癌患者的独立预后因素（风险比：0.420，95%置信区间：0.180 - 0.985，P = 0.042）。
血清甲状腺素运载蛋白的人体测量可用于预测胃癌患者的预后。
